fluoxetine has been researched along with Alcohol Problem in 3 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluoxetine was well tolerated in this treatment population." | 2.74 | Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder. ( Bukstein, OG; Clark, DB; Cornelius, JR; Douaihy, A; Kirisci, L; Wood, DS, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cornelius, JR | 3 |
| Bukstein, OG | 3 |
| Wood, DS | 2 |
| Kirisci, L | 1 |
| Douaihy, A | 2 |
| Clark, DB | 2 |
| Daley, DC | 1 |
| Wood, SD | 1 |
| Kelly, TM | 2 |
| Salloum, IM | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacological Intervention Project (Fluoxetine)[NCT00027378] | Phase 2 | 50 participants (Actual) | Interventional | 2001-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Alcohol use behaviors measured by drinks per week. (NCT00027378)
Timeframe: Average number of drinks as recorded on the Timeline Follow-Back (subject-reported) measure daily over the 12-week acute phase.
| Intervention | standard drink (14 gr. alcohol) (Mean) |
|---|---|
| Fluoxetine Plus Treatment As Usual (TAU) | 1.56 |
| Placebo Plus Treatment as Usual (TAU) | 1.73 |
Beck Depression Inventory (BDI) Scores measured at Weeks 1-4, 6, 8, 10, 12. The BDI is a subject reported measure that has a minimum score of 0 and a maximum score of 63. A better outcome would consist of values near the minimum end of the scale (0) and a worse outcome would consist of values near the maximum end of the scale (63). (NCT00027378)
Timeframe: Average score as measured by participant's report on the Beck Depression Inventory (BDI).
| Intervention | units on a scale (Mean) |
|---|---|
| Fluoxetine Plus Treatment As Usual (TAU) | 6.79 |
| Placebo Plus Treatment as Usual (TAU) | 10.46 |
2 trials available for fluoxetine and Alcohol Problem
| Article | Year |
|---|---|
Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder.
Topics: Adolescent; Adolescent Behavior; Alcohol-Related Disorders; Cognitive Behavioral Therapy; Comorbidit | 2009 |
Evaluation of cognitive behavioral therapy/motivational enhancement therapy (CBT/MET) in a treatment trial of comorbid MDD/AUD adolescents.
Topics: Adolescent; Alcohol-Related Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; Como | 2011 |
1 other study available for fluoxetine and Alcohol Problem
| Article | Year |
|---|---|
Fluoxetine in depressed AUD adolescents: a 1-year follow-up evaluation.
Topics: Adolescent; Adult; Alcohol-Related Disorders; Depressive Disorder, Major; Diagnosis, Dual (Psychiatr | 2004 |